Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects

NCT ID: NCT00356798

Last Updated: 2007-11-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-12-31
• Study Completion Date: 2006-04-30

Brief Summary

Based on pre-clinical trial data and principle of GCP, the objective of phase I clinical trial is to evaluate safety and immunogenicity of Pan-flu vaccine, an inactivated whole virion H5N1 vaccine with aluminium hydroxide adjuvant.

Conditions

Influenza

Keywords

pandemic; influenza; H5N1; vaccine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Interventions

an inactivated whole virion H5N1 vaccine, adjuvanted

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Males and females, age from 18 to 60 years old;
• Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process;
• Able and willing to complete the informed consent process.

Exclusion Criteria

• Woman who is breast-feeding or planning to become pregnant during the following 210 days of study participation;
• Persons who engage in the following occupations: culturist, slaughter, sale and forwarder of avian;
• Subject has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc;
• Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain;
• Autoimmune disease or immunodeficiency;
• Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or intravenous corticosteroids;
• Diabetes mellitus (type I or II), with the exception of gestational diabetes;
• History of thyroidectomy or thyroid disease that required medication within the past 12 months;
• Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years;
• Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws;
• Malignancy that is active or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study;
• Seizure disorder other than 1) febrile seizures under the age of two, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not requiring treatment within the last 3 years;
• Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen;
• Guillain-Barre Syndrome (GBS);
• Abnormal result of laboratory test as below:

• Biochemistry assaying: Alanine Aminotransferase /Serum Glutamate Pyruvate Transaminase (ALT), Total Bilirubine Tbil (TBIL), Direct Bilirubine Tbil (DBIL), Blood Urea Nitrogen (BUN) and Creatinine (Cr).
• Routine blood assaying, routine urine assaying.
• HBsAg positive;
• Pregnancy test positive for female;
• Subject has received any of the following substances:

• Immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis).
• Blood products within 3 months prior to initial study vaccine administration.
• Other study drug within 30 days prior to initial study vaccine administration. Live attenuated vaccines within 30 days prior to initial study vaccine administration.
• Medically indicated subunit or killed vaccines, e.g. pneumococcal, or allergy treatment with antigen injections, within 14 days of study vaccine administration.
• Current anti-TB prophylaxis or therapy.
• Fever before vaccination, axillary temperature 37.0 centigrades.
• Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment.
• Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ministry of Science and Technology of the People´s Republic of China

OTHER_GOV

Sponsor Role: collaborator

Sinovac Biotech Co., Ltd

INDUSTRY

Sponsor Role: lead

Principal Investigators

Jiangtao Lin, MD

Role: PRINCIPAL_INVESTIGATOR

China-Japan Friendship Hospital

Locations

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

Countries

China

References

Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006 Sep 16;368(9540):991-7. doi: 10.1016/S0140-6736(06)69294-5.

Reference Type: RESULT

PMID: 16980114 (View on PubMed)

Other Identifiers

PRO-PanFlu-1001

Identifier Type: -

Identifier Source: org_study_id